Deborah Dukovic

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial

Christian Confavreux, Paul O’Connor, Mark Freedman et al. · The Lancet Neurology · 2014 · 566 citations

Oral Teriflunomide, Neurological Disorder, Medicine +6

Leukocyte Count as an Independent Predictor of Recurrent Ischemic Events

Armin Grau, Alexander W. Boddy, Deborah Dukovic et al. · Stroke · 2004 · 313 citations

Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions

Mark Freedman, Ludwig Kappos, Tomas Olsson et al. · Multiple Sclerosis and Related Disorders · 2015 · 88 citations · Full text

Teriflunomide Increases the Proportion of Patients Free from Disease Activity in the TEMSO Phase III Study (PD5.007)

M. S. Freedman, P. O’Connor, J. S. Wolinsky et al. · Neurology · 2012 · 15 citations

Disease Management, Disease Progression, Composite Endpoint +8